FDA Warns of Prescription Errors with Similar Brand Names

The FDA warns of prescription errors due to similar brand names: Brilinta (ticagrelor) and Brintellix (vortioxetine). PGXL reports are designed to provide both brand and generic drug names to reduce these types of errors, including for these two medications.

The U.S. Food and Drug Administration is warning health care professionals and patients that reports of confusion between the antidepressant Brintellix and anti-blood clotting medication Brilinta have resulted in the wrong medication being prescribed or dispensed. We have determined that the main reason for the confusion between these two medications is the similarity of their brand (proprietary) names. None of the reports indicates that a patient ingested the wrong medication; however, reports of prescribing and dispensing errors continue. As a result, we are alerting the public about this safety issue.

Read the Full Article Here

by Content_Management
This entry was posted in News. Bookmark the permalink.

Comments are closed.